Cost-effectiveness analysis of schizophrenic patient care settings: Impact of an atypical antipsychotic under long-acting injection formulation;Analyse coût-efficacité des stratégies de prise en charge des patients schizophrènes: Place d'un antipsychotique atypique sous forme injectable à libération prolongée

Encephale

Volumn 31, Issue 2, 2005, Pages 235-246

  Llorca, P M ^a   Miadi Fargier, H ^b   Lancon C ^d   Mosqueda, G Jasso ^b   Casadebaig, F ^e   Philippe, A ^e   Guillon, P ^f   Mehnert, A ^g   Omnes L F ^b   Chicoye, A ^b   Durand Zaleski, I ^c  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b Aremis Consultants   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d HÔPITAL SAINTE MARGUERITE   (France)

^e INSERM   (France)

^f Laboratoires Janssen CILAG   (France)

^g JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Antipsychotics; Cost effectiveness; Decision tree; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; HALOPERIDOL DECANOATE; LONG ACTING DRUG; OLANZAPINE; RISPERIDONE;

AMBULATORY CARE; ARTICLE; COGNITION; COST EFFECTIVENESS ANALYSIS; DEATH; DIABETES MELLITUS; DIAGNOSIS RELATED GROUP; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FRANCE; HEALTH CARE UTILIZATION; HOSPITAL CARE; HOSPITAL COST; HUMAN; OBESITY; PATIENT COMPLIANCE; PENSION; PRODUCTIVITY; REIMBURSEMENT; RELAPSE; SCHIZOPHRENIA; SOCIAL SUPPORT; SOCIAL WELFARE; TARDIVE DYSKINESIA;

EID: 21044436423     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0013-7006(05)82390-5     Document Type: Article

References (19)

1. ALMOND S, O'DONNELL O. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 2000; 17 (4): 383-9.
2. BARNES TR, CURSON DA. Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf 1994; 10 (6): 464-79.
3. e éd. Paris: Masson; 1995.
4. MINISTÈRE DU TRAVAIL ET DES AFFAIRES SOCIALES. Bulletin Officiel Solidarité Santé, n° 96/6bis, 1996.
5. CASADEBAIG F, RUFFIN D, QUEMADA N. Caractéristique de la population prise en charge par les secteurs de psychiatrie géné rale en 1993 et 1998. Évolution clinique et démographique. Rev Epidemiol Sant Publ 2001; 49: 513-21.
6. CHUE et al. Hospitalisation rates in patients during long-term treatment with long-acting risperidone injection. Int J Clin Neuropsychopharmacol 2002: 5 (Suppl 1): S128-9.
7. CHUE PS, DEVOS E, DUCHESNE IY et al. One year hospitalisation rates in patients with schizophrenia during long-term treatment with long-acting risperidone. Val Health 2002; 5 (3): 229.
8. CSERNANSKY JG, MAHMOUD R, BRENNER R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346 (1): 16-22.
9. EERDEKENS et al. Long-term safety and efficacy of Risperdal Consta TM, the long-acting injection formulation of risperidone. Int J Clin Neuropsychopharmacol 2002; 5 (Suppl 1): S126.
10. FÉDÉRATION FRANÇAISE DE PSYCHIATRIE. Conférence de Consensus - Stratégies thérapeutiques à long terme dans les psychoses schizophréniques. Paris, 13-14 janvier 1994.
11. FOSTER RH, GOA KL. Olanzapine: a pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1999; 15 (6):611-40.
12. FRATTA A, GURY C, PETIT JEAN F et al. Olanzapine dans le traitement de la schizophrénie. Évaluation clinique. Dos CNHIM 2002; XXIII: 1.
13. GAEBEL W, PIETZCKER A. Prospective study of course of illness in schizophrenia: part III. Treatment and outcome. Schizophr Bull 1987; 13 (2): 307-16.
14. GERLACH J. Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol. 1995; 9 (Suppl 5): 17-20.
15. HEYSCUE BE, LEVIN GM, MERRICK JP. Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatr Serv 1998; 49 (9): 1232-4.
16. RABINOWITZ J, LICHTENBERG P, KAPLAN Z et al. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001; 158 (2): 266-9.
17. REMINGTON GJ, ADAMS ME. Depot neuroleptic therapy: clinical considerations. Can J Psychiatry 1995; 40 (Suppl 1): S5-11.
18. ROUILLON F, DANSETTE GY, LE FLOCH C. Etude de la prise en charge thérapeutique des schizophrènes et son coût. Encephale 1994; 20: 303-9.
19. ROUILLON F, TOUMI M, DANSETTE GY et al. Some aspects of the costs of schizophrenia in France. Pharmacoeconomics 1997; 11 (6): 578-94.